E-therapeutics (ETX) secured its funding needs for the next four years after the biotech secured a notable £40m fundraising. The proceeds from the raising will boost the company's cash resources to £48m, more than its current market capitalisation. E-Therapeutics' ability to raise money, particularly with heavyweight backing from Invesco, was noted two years ago when it first raised £17m in a tight market. But the difference this time is that e-Therapeutics is taking a much clearer view about what sort of products it wants to develop.
To continue reading, register today
to enjoy limited access to the following:
- Daily trading news
- Funds coverage
- Features on big investment themes
- Comprehensive companies coverage
- Economic analysis